Conference Highlights: The 2010 Veith Symposium

The 37th annual Veith Symposium was held from November 17 to 21 in New York City. The features below highlight some of the news emerging from the meeting. Analyzing Different Stenting Approaches for Restenosis The Particulars: Few studies have compared the use of drug-eluting stents after angioplasty with balloon angioplasty and bare-metal stenting in the treatment of restenosis. The Zilver PTX (Cook Medical, Inc.) is the first drug-eluting stent approved for the superficial femoral artery and is currently under investigation in the United States for use in restenosis. Researchers conducted a study comparing the Zilver PTX drug-eluting stent after angioplasty with balloon angioplasty and bare-metal stenting. Data Breakdown: The study enrolled 479 patients at 56 institutions in the United States, Japan, and Germany, with 241 patients randomized to the Zilver PTX group and 238 to the bare-metal stenting group. Demographics and lesion characteristics were similar for the groups. Approximately, half of the bare-metal stenting group experienced acute failure and underwent secondary randomization in which 59 and 61 patients were assigned to provisional stenting with Zilver bare-metal stents and Zilver PTX, respectively. Study results met the 12-month primary endpoint goals showing non-inferiority and superior patency for the Zilver PTX as compared with a bare-metal stenting group. Endpoints included event-free survival, stent integrity by radiographic core laboratory analysis, and primary patency by Duplex ultrasound core laboratory analysis. There was also significant clinical improvement with the Zilver PTX. Take Home Pearl: The Zilver PTX drug-eluting peripheral stent appears to be safe and effective for the treatment of restenosis when compared with bare-metal stenting. Ultrasound-Accelerated CDT Beneficial in PE Treatment The Particulars: Pulmonary...